PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jvirolPermissionsJournals.ASM.orgJournalJV ArticleJournal InfoAuthorsReviewers
 
J Virol. 1995 June; 69(6): 3704–3711.
PMCID: PMC189086

Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.

Abstract

Cats were immunized three times with different recombinant feline immunodeficiency virus (FIV) candidate vaccines. Recombinant vaccinia virus (rVV)-expressed envelope glycoprotein with (vGR657) or without (vGR657 x 15) the cleavage site and an FIV envelope bacterial fusion protein (beta-Galactosidase-Env) were incorporated into immune-stimulating complexes or adjuvanted with Quil A. Although all immunized cats developed antibodies against the envelope protein, only the cats vaccinated with the rVV-expressed envelope glycoproteins developed antibodies which neutralized FIV infection of Crandell feline kidney cells. These antibodies failed to neutralize infection of thymocytes with a molecularly cloned homologous FIV. After the third immunization the cats were challenged with homologous FIV. Two weeks after challenge the cell-associated viral load proved to be significantly higher in the cats immunized with vGR657 and vGR657 x 15 than in the other cats. The cats immunized with vGR657 and vGR657 x 15 also developed antibodies against the Gag proteins more rapidly than the cats immunized with beta-Galactosidase-Env or the control cats. This suggested that immunization with rVV-expressed glycoprotein of FIV results in enhanced infectivity of FIV. It was shown that the observed enhancement could be transferred to naive cats with plasma collected at the day of challenge.

Full Text

The Full Text of this article is available as a PDF (288K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ackley CD, Yamamoto JK, Levy N, Pedersen NC, Cooper MD. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol. 1990 Nov;64(11):5652–5655. [PMC free article] [PubMed]
  • Arthur LO, Bess JW, Jr, Waters DJ, Pyle SW, Kelliher JC, Nara PL, Krohn K, Robey WG, Langlois AJ, Gallo RC, et al. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J Virol. 1989 Dec;63(12):5046–5053. [PMC free article] [PubMed]
  • Barlough JE, Ackley CD, George JW, Levy N, Acevedo R, Moore PF, Rideout BA, Cooper MD, Pedersen NC. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infections. J Acquir Immune Defic Syndr. 1991;4(3):219–227. [PubMed]
  • Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. [PubMed]
  • Berman PW, Groopman JE, Gregory T, Clapham PR, Weiss RA, Ferriani R, Riddle L, Shimasaki C, Lucas C, Lasky LA, et al. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5200–5204. [PubMed]
  • Carlson JR, McGraw TP, Keddie E, Yee JL, Rosenthal A, Langlois AJ, Dickover R, Donovan R, Luciw PA, Jennings MB, et al. Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1239–1246. [PubMed]
  • Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. [PubMed]
  • de Ronde A, Stam JG, Boers P, Langedijk H, Meloen R, Hesselink W, Keldermans LC, van Vliet A, Verschoor EJ, Horzinek MC, et al. Antibody response in cats to the envelope proteins of feline immunodeficiency virus: identification of an immunodominant neutralization domain. Virology. 1994 Jan;198(1):257–264. [PubMed]
  • Dow SW, Poss ML, Hoover EA. Feline immunodeficiency virus: a neurotropic lentivirus. J Acquir Immune Defic Syndr. 1990;3(7):658–668. [PubMed]
  • Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, Putney SD, Matsushita S, Cobb KE, Jett CM, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. [PubMed]
  • Heeney JL, van Els C, de Vries P, ten Haaft P, Otting N, Koornstra W, Boes J, Dubbes R, Niphuis H, Dings M, et al. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Exp Med. 1994 Aug 1;180(2):769–774. [PMC free article] [PubMed]
  • Hoffmann-Fezer G, Thum J, Ackley C, Herbold M, Mysliwietz J, Thefeld S, Hartmann K, Kraft W. Decline in CD4+ cell numbers in cats with naturally acquired feline immunodeficiency virus infection. J Virol. 1992 Mar;66(3):1484–1488. [PMC free article] [PubMed]
  • Hohdatsu T, Pu R, Torres BA, Trujillo S, Gardner MB, Yamamoto JK. Passive antibody protection of cats against feline immunodeficiency virus infection. J Virol. 1993 Apr;67(4):2344–2348. [PMC free article] [PubMed]
  • Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol. 1990 Apr;64(4):1437–1440. [PMC free article] [PubMed]
  • Homsy J, Meyer M, Tateno M, Clarkson S, Levy JA. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science. 1989 Jun 16;244(4910):1357–1360. [PubMed]
  • Hosie MJ, Osborne R, Reid G, Neil JC, Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol. 1992 Dec;35(1-2):191–197. [PubMed]
  • Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992 Jan 24;255(5043):456–459. [PubMed]
  • Hu SL, Fultz PN, McClure HM, Eichberg JW, Thomas EK, Zarling J, Singhal MC, Kosowski SG, Swenson RB, Anderson DC, et al. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 1987 Aug 20;328(6132):721–723. [PubMed]
  • Hurtrel M, Ganière JP, Guelfi JF, Chakrabarti L, Maire MA, Gray F, Montagnier L, Hurtrel B. Comparison of early and late feline immunodeficiency virus encephalopathies. AIDS. 1992 Apr;6(4):399–406. [PubMed]
  • Johnson PR, Montefiori DC, Goldstein S, Hamm TE, Zhou J, Kitov S, Haigwood NL, Misher L, London WT, Gerin JL, et al. Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1501–1505. [PubMed]
  • Kurth R, Binninger D, Ennen J, Denner J, Hartung S, Norley S. The quest for an AIDS vaccine: the state of the art and current challenges. AIDS Res Hum Retroviruses. 1991 May;7(5):425–433. [PubMed]
  • Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, Benveniste RE. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science. 1992 Jan 24;255(5043):456–459. [PubMed]
  • Lewis MG, Elkins WR, McCutchan FE, Benveniste RE, Lai CY, Montefiori DC, Burke DS, Eddy GA, Shafferman A. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine. 1993 Oct;11(13):1347–1355. [PubMed]
  • Lombardi S, Garzelli C, La Rosa C, Zaccaro L, Specter S, Malvaldi G, Tozzini F, Esposito F, Bendinelli M. Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol. 1993 Aug;67(8):4742–4749. [PMC free article] [PubMed]
  • Lombardi S, Garzelli C, Pistello M, Massi C, Matteucci D, Baldinotti F, Cammarota G, da Prato L, Bandecchi P, Tozzini F, et al. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol. 1994 Dec;68(12):8374–8379. [PMC free article] [PubMed]
  • Montefiori DC, Robinson WE, Jr, Hirsch VM, Modliszewski A, Mitchell WM, Johnson PR. Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol. 1990 Jan;64(1):113–119. [PMC free article] [PubMed]
  • Osterhaus A, de Vries P, Heeney J. AIDS vaccine developments. Nature. 1992 Feb 20;355(6362):684–685. [PubMed]
  • Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science. 1987 Feb 13;235(4790):790–793. [PubMed]
  • Putkonen P, Thorstensson R, Albert J, Hild K, Norrby E, Biberfeld P, Biberfeld G. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS. 1990 Aug;4(8):783–789. [PubMed]
  • Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, Norrby E. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature. 1991 Aug 1;352(6334):436–438. [PubMed]
  • Putkonen P, Thorstensson R, Walther L, Albert J, Akerblom L, Granquist O, Wadell G, Norrby E, Biberfeld G. Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retroviruses. 1991 Mar;7(3):271–277. [PubMed]
  • Rimmelzwaan GF, Siebelink KH, Huisman RC, Moss B, Francis MJ, Osterhaus AD. Removal of the cleavage site of recombinant feline immunodeficiency virus envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes. J Gen Virol. 1994 Aug;75(Pt 8):2097–2102. [PubMed]
  • Robinson WE, Jr, Kawamura T, Lake D, Masuho Y, Mitchell WM, Hersh EM. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol. 1990 Nov;64(11):5301–5305. [PMC free article] [PubMed]
  • Robinson WE, Jr, Montefiori DC, Mitchell WM, Prince AM, Alter HJ, Dreesman GR, Eichberg JW. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4710–4714. [PubMed]
  • Schlienger K, Montefiori DC, Mancini M, Rivière Y, Tiollais P, Michel ML. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J Virol. 1994 Oct;68(10):6578–6588. [PMC free article] [PubMed]
  • Schutten M, Andeweg AC, Bosch ML, Osterhaus AD. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand J Immunol. 1995 Jan;41(1):18–22. [PubMed]
  • Shafferman A, Jahrling PB, Benveniste RE, Lewis MG, Phipps TJ, Eden-McCutchan F, Sadoff J, Eddy GA, Burke DS. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7126–7130. [PubMed]
  • Shelton GH, Linenberger ML, Grant CK, Abkowitz JL. Hematologic manifestations of feline immunodeficiency virus infection. Blood. 1990 Sep 15;76(6):1104–1109. [PubMed]
  • Siebelink CH, Windrich RW, Chu I, Groen J, Weijer K, UytdeHaag FG, Osterhaus AD. An enzyme linked immunosorbent assay (ELISA) for the detection of feline immunodeficiency virus (FIV) antigen in cell culture and FIV specific antibodies in feline serum. Dev Biol Stand. 1990;72:189–196. [PubMed]
  • Siebelink KH, Chu IH, Rimmelzwaan GF, Weijer K, van Herwijnen R, Knell P, Egberink HF, Bosch ML, Osterhaus AD. Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function. AIDS Res Hum Retroviruses. 1990 Dec;6(12):1373–1378. [PubMed]
  • Siebelink KH, Chu IH, Rimmelzwaan GF, Weijer K, Osterhaus AD, Bosch ML. Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. J Virol. 1992 Feb;66(2):1091–1097. [PMC free article] [PubMed]
  • Siebelink KH, Rimmelzwaan GF, Bosch ML, Meloen RH, Osterhaus AD. A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol. 1993 Apr;67(4):2202–2208. [PMC free article] [PubMed]
  • Sparger EE, Luciw PA, Elder JH, Yamamoto JK, Lowenstine LJ, Pedersen NC. Feline immunodeficiency virus is a lentivirus associated with an AIDS-like disease in cats. AIDS. 1989;3 (Suppl 1):S43–S49. [PubMed]
  • Stott EJ. Anti-cell antibody in macaques. Nature. 1991 Oct 3;353(6343):393–393. [PubMed]
  • Takeda A, Ennis FA. FcR-mediated enhancement of HIV-1 infection by antibody. AIDS Res Hum Retroviruses. 1990 Aug;6(8):999–1004. [PubMed]
  • Yamamoto JK, Hohdatsu T, Olmsted RA, Pu R, Louie H, Zochlinski HA, Acevedo V, Johnson HM, Soulds GA, Gardner MB. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol. 1993 Jan;67(1):601–605. [PMC free article] [PubMed]
  • Yamamoto JK, Okuda T, Ackley CD, Louie H, Pembroke E, Zochlinski H, Munn RJ, Gardner MB. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res Hum Retroviruses. 1991 Nov;7(11):911–922. [PubMed]
  • Yamamoto JK, Sparger E, Ho EW, Andersen PR, O'Connor TP, Mandell CP, Lowenstine L, Munn R, Pedersen NC. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res. 1988 Aug;49(8):1246–1258. [PubMed]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)